Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Stemline Therapeutics Inc.

www.stemline.com

Latest From Stemline Therapeutics Inc.

Novartis Snaps Up KRAS Inhibitor R&D

Novartis has taken an option on novel inhibitors of the KRAS cell signaling pathway while it funds the drug discovery research at the Cancer Research UK’s Beatson Institute.

Deals Cancer

Medicare New Technology Add-On Payment Awards For Hospital Drugs On The Rise

Eight inpatient prescription drugs are deemed eligible for supplemental payments in 2020, a big increase from years past, based on a review of US Medicare's new technology add-on payment approvals for prescription drugs since 2011. 

Medicare Reimbursement

Finance Watch: A Rough Week To End A Bad Month For Biotech Stocks

Public Company Edition: The prior day's after-hours bad news sent biotech stocks lower on 9 August, and IPOs are taking a breather with the NBI down 2.1% over the past month. However, already public companies are raising cash, including Allakos and Ironwood at $350m each.

Financing Business Strategies

Novartis’s Zolgensma Loses EU Accelerated Assessment

Companies pleased at gaining an EU accelerated assessment for a product should be aware that the agency offers no guarantee that they will get to keep it. Novartis’s Zolgensma is one of seven drugs whose review the EMA has taken off the fast track.

Europe Drug Review
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
    • Vaccines
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Stemline Therapeutics Inc.
  • Senior Management
  • Ivan Bergstein, MD, Pres. & CEO
    Kenneth Hoberman, COO
    David Gionco, VP, Fin. & Chief Accounting Officer
    Robert M Francomano, Chief Commercial Officer
  • Contact Info
  • Stemline Therapeutics Inc.
    Phone: (646) 502-2310
    750 Lexington Ave.
    11th Fl.
    New York, NY 10022
    USA
UsernamePublicRestriction

Register